PDS Bio (PDSB) Stock Forecast, Price Target & Predictions
PDSB Stock Forecast
PDS Bio stock forecast is as follows: an average price target of $9.00 (represents a 200.00% upside from PDSB’s last price of $3.00) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PDSB Price Target
The average price target for PDS Bio (PDSB) is $9.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 200.00% upside from PDSB's last price of $3.00.
PDSB Analyst Ratings
According to 2 Wall Street analysts, PDS Bio's rating consensus is 'Buy'. The analyst rating breakdown for PDSB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PDS Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 12, 2024 | Mayank Mamtani | B.Riley Financial | $9.00 | $2.76 | 226.09% | 200.00% |
| Mar 28, 2024 | Mayank Mamtani | B.Riley Financial | $11.00 | $3.85 | 185.71% | 266.67% |
The latest PDS Bio stock forecast, released on Jun 12, 2024 by Mayank Mamtani from B.Riley Financial, set a price target of $9.00, which represents a 226.09% increase from the stock price at the time of the forecast ($2.76), and a 200.00% increase from PDSB last price ($3.00).
PDS Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $3.00 | $3.00 | $3.00 |
| Upside/Downside | -100.00% | -100.00% | 233.33% |
In the current month, the average price target of PDS Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PDS Bio's last price of $3.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 20, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Mar 28, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Nov 15, 2022 | Chardan Capital | Buy | Buy | Hold |
| May 13, 2022 | Alliance Global Partners | Buy | Buy | Hold |
PDS Bio's last stock rating was published by Alliance Global Partners on Aug 20, 2024. The company gave PDSB a "Buy" rating, the same as its previous rate.
PDS Bio Financial Forecast
PDS Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PDSB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PDS Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PDSB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PDS Bio's previous annual EBITDA (undefined) of $NaN.
PDS Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-10.64M | $-10.27M | $-11.01M | $-10.64M | $-12.84M | $-11.60M | $-11.99M |
| High Forecast | $-10.64M | $-10.27M | $-11.01M | $-10.64M | $-12.84M | $-10.47M | $-11.99M |
| Low Forecast | $-10.64M | $-10.27M | $-11.01M | $-10.64M | $-12.84M | $-12.34M | $-11.99M |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PDSB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PDS Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PDSB last annual SG&A of $NaN (undefined).
PDS Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.29 | $-0.35 | $-0.32 | $-0.33 |
| High Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.29 | $-0.35 | $-0.29 | $-0.33 |
| Low Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.29 | $-0.35 | $-0.34 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PDS Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PDSB previous annual EPS of $NaN (undefined).
PDS Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
PDSB Forecast FAQ
Is PDS Bio a good buy?
Yes, according to 2 Wall Street analysts, PDS Bio (PDSB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PDSB's total ratings.
What is PDSB's price target?
PDS Bio (PDSB) average price target is $9 with a range of $9 to $9, implying a 200.00% from its last price of $3. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PDS Bio stock go up soon?
According to Wall Street analysts' prediction for PDSB stock, the company can go up by 200.00% (from the last price of $3 to the average price target of $9), up by 200.00% based on the highest stock price target, and up by 200.00% based on the lowest stock price target.
Can PDS Bio stock reach $4?
PDSB's average twelve months analyst stock price target of $9 supports the claim that PDS Bio can reach $4 in the near future.
What are PDS Bio's analysts' financial forecasts?
PDS Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-36.425M (high $-35.303M, low $-37.173M), average SG&A $0 (high $0, low $0), and average EPS is $-0.993 (high $-0.962, low $-1.013). PDSB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.565M (high $-42.565M, low $-42.565M), average SG&A $0 (high $0, low $0), and average EPS is $-1.16 (high $-1.16, low $-1.16).